Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: SkyQuest | PRODUCT CODE: 1458092

Cover Image

PUBLISHER: SkyQuest | PRODUCT CODE: 1458092

Global Diabetic Retinopathy Market Size, Share, Growth Analysis, By Type(Proliferative Diabetic Retinopathy, and Non-proliferative diabetic retinopathy), By Management(Anti-VEGF, Intraocular Steroid Injection) - Industry Forecast 2024-2031

PUBLISHED:
PAGES: 219 Pages
DELIVERY TIME: 3-5 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5300
PDF & Excel (Multiple User License)
USD 6200
PDF & Excel (Enterprise License)
USD 7100

Add to Cart

Global Diabetic Retinopathy Market size was valued at USD 8.30 billion in 2022 and is poised to grow from USD 8.83 billion in 2023 to USD 14.51 billion by 2031, growing at a CAGR of 6.4% during the forecast period (2024-2031).

The market expansion is expected to be propelled by several factors including the increasing incidence of diabetes, a growing aging population, and the rise in diabetes-related blindness. Additionally, heightened awareness of diabetes and the introduction of new products are contributing to market growth. Diabetes, a prevalent global condition characterized by the pancreas' inability to produce insulin, leads to elevated blood sugar levels and damage to retinal blood capillaries, resulting in diabetic retinopathy. High blood sugar levels and inadequate monitoring are considered risk factors for retinal degeneration, but early detection of diabetes, proper medication, continuous self-monitoring using modern tools, and embracing a healthy lifestyle can mitigate retinal damage and lower the incidence of diabetic retinopathy. Despite preventive efforts, diabetic retinopathy can lead to irreversible blindness, necessitating early detection strategies like those offered by Check Eye, a healthtech company leveraging AI to screen for diabetic retinopathy. In the UK, diabetic retinopathy ranks among the leading causes of blindness, underscoring the importance of consumer awareness and increased healthcare spending. Moreover, with the global aging population projected to triple by 2050, maintaining a healthy lifestyle and regular blood glucose monitoring are imperative to mitigate the risks associated with diabetes and its complications.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Diabetic Retinopathy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Diabetic Retinopathy Market Segmental Analysis

The global diabetic retinopathy market is segmented based on type, management, and region. Based on type, the market is segmented into proliferative diabetic retinopathy, and non-proliferative diabetic retinopathy. With respect to categorization by management, the market is segmented into anti-VEGF, intraocular steroid injection, laser surgery, vitrectomy. Regionwise, the market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.

Drivers of the Global Diabetic Retinopathy Market

The diabetic retinopathy market is witnessing significant expansion, propelled by augmented investments in healthcare infrastructure, which foster improved healthcare provision and accessibility. Concurrently, concerted endeavors by public and private entities to boost awareness regarding diabetic retinopathy are bolstering market growth. Furthermore, favorable reimbursement conditions and a populace with substantial disposable income are fostering the market's expansion. The demographic shift towards an aging population, coupled with evolving lifestyles, further accelerates the market's growth trajectory.

Restraints in the Global Diabetic Retinopathy Market

The increasing occurrence of diabetic retinopathy is accompanied by insufficient awareness regarding the condition and the necessity of regular eye check-ups among individuals with diabetes. Restricted availability of eye care services, especially in remote or underserved regions, poses obstacles to early detection and prompt intervention.

Market Trends of the Global Diabetic Retinopathy Market

Increasingly acknowledged is the pivotal role of early detection and intervention in addressing diabetic retinopathy, with emphasis shifting towards implementing routine screening initiatives, raising awareness through campaigns, and adopting cutting-edge imaging techniques to facilitate prompt diagnosis, thereby enabling timely therapeutic interventions and more effective disease management.

Product Code: SQMIG35A2516

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global Diabetic Retinopathy Market by Type

  • Market Overview
  • Proliferative Diabetic Retinopathy
  • and Non-proliferative diabetic retinopathy

Global Diabetic Retinopathy Market by Management

  • Market Overview
  • Anti-VEGF
  • Intraocular Steroid Injection
  • Laser Surgery
  • and Vitrectomy

Global Diabetic Retinopathy Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021

Key Company Profiles

  • Novartis AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Roche Holding AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Regeneron Pharmaceuticals, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Allergan plc (AbbVie Inc.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Carl Zeiss Meditec AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Topcon Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Nidek Co., Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Optos plc (Nikon Corporation)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bausch Health Companies Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Alcon Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Santen Pharmaceutical Co., Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Lumenis Ltd. (XIO Group)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Iridex Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Leica Microsystems (Danaher Corporation)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • StemCells Inc. (Microbot Medical Inc.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bioptigen, Inc. (Metabolic Technologies Inc.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • CenterVue SpA
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Visunex Medical Systems, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Clarity Medical Systems, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!